Abstract:Objective To investigate mutation status of isocitrate dehydrogenase (IDH) 1 and IDH2 genes in Chinese patients with gliomas in correlation with clinicopathological characteristics.Methods Formalin-fixed and paraffin-embedded (FFPE) tissue samples of 234 gliomas were collected including the matched blood samples in 30 patients.DNA was extracted,followed by PCR-Sanger sequencing to detect IDH1 and IDH2 gene mutations.Immunohistochemistry was performed using mutation-specific antibody recognizing IDH1R132H mutation.Immunostains for p53 and epidermal growth factor receptor (EGFR) were also performed.Oligodendroglial tumors with IDH mutation were double stained with IDH1R132H and GFAP by immunofluorescence to investigate the location of IDH1 R132H expression.Results (1) By IDH1 heterozygous somatic mutation analysis,Arg132His (c:G395A) was found in 31.6％ (74 of 234) of the cases.IDH mutations were more frequent in oligoastrocytomas (9/13),anaplastic oligoastrocytomas (7/11),oligodendrogliomas (18/26,69.2％),anaplastic oligodendrogliomas (8/10),and less frequent in diffuse astrocytomas (17/47,36.2％),anaplastic astrocytomas (5/18),and glioblastomas (10/69,14.5％).The mutation rate inversely correlated with the tumor grade in a linear fashion in astrocytic tumors (P =0.007).Primary glioblastomas were characterized by a lower frequency of mutations than secondary glioblastomas (5/55 vs.5/14,P =0.036); IDH mutation was not detected in pilocytic astrocytoma and ependymoma.No IDH2 mutation was identified in this study cohort.(2) Immunohistochemistry of IDH1R132H demonstrated a strong cytoplasmic staining in 80 cases,which was highly correlated with IDH mutation status (P =0.001).IDH1R132H was highly specific to tumor cells.(3) p53 immunostain was significantly correlated the IDH mutation in diffuse astrocytoma,anaplastic astrocytoma and secondary glioblastomas (P =0.007,0.026,0.038 respectively).(4) No correlation between EGFR and IDH mutation was found.Conclusions High prevalence of IDH heterozygous somatic mutation occurs in the earlier stage of gliomas,which can be detected by mutation-specific antibody IDH1R132H.Furthermore,evaluation of p53 and EGFR expression combined with IDH mutation analysis may significantly aid in the diagnosis and differential diagnoses of gliomas in Chinese patients.

The study on mutation and MSI of LGI 1 in glioma

Expression of leucine-rich gene glioma inactivated 1 in glioma

Expression and Significance of Isocitrate Dehydrogenase 1 Mutation in Human Glioma

Expression Studies in Gliomas and Glial Cells Do Not Support a Tumor Suppressor Role for LGI11

Study on the Single Nucleotide Polymorphysims of the Susceptibility Genes in Patients with Glioma

Study of germline mutation of hMSH2,hMSH6 and hMLH1 and methylation of hMLH1 in microsatellite instability colorectal cancer

Mutation of isocitrate dehydrogenase gene in Chinese patients with glioma

Diagnostic and prognostic value of IDH1 mutation in gliomas

Analysis of 1p/19q Codeletion in Gliomas:Report of 63 Cases

Detection of MMP Family Levels in Lateral Fissure Area Low Grade Glioma and Prognosis

Molecular Genetic Alterations, Pathology and Clinical Prognosis in Oligodendroglial Tumors

Molecular and clinical characterization of IDH associated immune signature in lower-grade gliomas

Molecular mechanisms associated with chromosomal and microsatellite instability in sporadic glioblastoma multiforme

Individual structural abnormality indexes are associated with molecular, histological and cognitive indicators for glioma patients Running title:Anoninvasive way to glioma malignancy

Loss of heterozygosity of chromosome 1p/19q and p53 protein expression in oligodendroglioma

Comparative study of IDH1 mutations in gliomas by high resolution melting analysis, immunohistochemistry and direct DNA sequencing

Possible Role of Isocitrate Dehydrogenase Gene Mutation in the Genesis of Glioma

Somatic Mutations in Myeloid Cell Leukemia-1 Contribute to the Pathogenesis of Glioma by Prolonging Its Half-Life.

Change of serum level of β2-microglobulin in patients with glioma

Heterogeneity of O6-methylguanine-DNA methyltransferase protein expression and gene promoter methylation in glioblastoma

Expression and Mutation Analysis of Cyclin A and Ki-67 in Glioma and Their Correlation with Tumor Progression